ClinicalTrials.Veeva

Menu
K

Kaohsiung Veterans General Hospital | Department of Allergy, Immunology and Rheumatology

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SHJ002
Sisunatovir
PF-06700841
Hydroxyurea
Ropeginterferon Alfa-2b
P1101
Anagrelide
Cyclophosphamide
nicardipine hydrochloride
Interferon

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

1 of 19 total trials

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101...

Active, not recruiting
Essential Thrombocythemia
Drug: Anagrelide
Biological: Ropeginterferon alfa-2b

Trial sponsors

K
Pfizer logo
A
B
D
Moderna logo
O
P
S
U

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems